Recommended dilution: IHC: 1:100 - 1:200 Positive and negative controls should be simultaneously run with unknown specimens, as there are no conclusive characteristics to suggest instability of the antibody. The prediluted antibody does not require any mixing, dilution, reconstitution, or titration; the antibody is ready-to-use and optimized for staining. The concentrated antibody requires dilution in the optimized buffer, to the recommended working dilution range (as above).
My Review for Mouse Anti-Human CD7 monoclonal antibody, clone JID652
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
References
Primary Enteropathy-Associated T-Cell Lymphoma Type 2: An Emerging Entity?
CANCER CONTROL
Authors: Grigg-Gutierrez, Nicole M.; Estremera-Marcial, Rodolfo; Caceres, William W.; Toro, Doris H.
Intestinal T-cell lymphoma is a rare hematological malignancy that can present as primary intestinal lymphoma or as a manifestation of systemic disease. Primary involvement accounts for approximately 0.1% to 0.5% of all colorectal neoplasms. It is an aggressive disease with a poor prognosis and low survival rate. Inflammatory bowel disease, celiac disease, immunosuppression, and infectious etiologies, such as Epstein-Barr and human T-lymphotropic viruses, have been reported as risk factors, but no direct causal link has been established. Herein, we examine the case of a Hispanic man 69 years of age diagnosed with positive CD3, CD7, CD8, CD43, and Bcl-2 diffuse primary colorectal T-cell lymphoma. The patient did not exhibit a concomitant autoimmune or genetic disease. Because of the patient's history of polyps, surveillance colonoscopy was performed and the diagnosis was confirmed.
Unilesional Follicular Mycosis Fungoides: Report of 6 Cases and Review of the Literature
AMERICAN JOURNAL OF DERMATOPATHOLOGY
Authors: Magro, Cynthia M.; Telang, Gladys H.; Momtahen, Shabnam
Unilesional follicular mycosis fungoides (MF) is a rare variant of cutaneous T-cell lymphoma characterized by selective involvement of the hair follicles by neoplastic T lymphocytes presenting initially as a solitary lesion occupying less than 5% of the body surface; there are 22 previous reported cases. We describe 6 patients with this rare variant of MF, all males (age range 6-64 years; mean age: 28 years) presenting with a solitary lesion primarily on the face and scalp except 1 patient who presented with a truncal lesion. All the patients had the lesions for at least a few months. The lesions were associated with follicular prominence and hair loss. In each, the biopsies showed an atypical folliculotropic lymphocytic infiltrate accompanied by follicular mucinosis in certain cases. The infiltrate involved the lower isthmic part of the follicle, and in 1 case, there was an alopecia areata-like neoplastic lymphomatoid bulbitis. There was no evidence of large cell transformation nor was there a significant degree of infiltration of the interfollicular dermis or epidermis. Higher magnification disclosed marked cerebriform atypia amidst the lymphocytes. Phenotypic studies demonstrated a high CD4 to CD8 ratio in excess of 5 with a significant loss of CD7. One patient developed additional similar lesions involving the thigh and buttock after a period of at least 3-4 years of untreated unilesional MF. Unilesional follicular MF is a potentially curable form of MF with a young male predilection. Early diagnosis and treatment intervention likely define a cornerstone for ensuring the best patient outcome and preventing clinical evolution to either tumor stage MF and or multilesional MF.